Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants
New England Journal of Medicine · 2023
DOI: 10.1056/nejmc2304780 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Maria Jose Soler und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Kidney Diseases, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA.
- Mayo Clinic College of Medicine and Science, Rochester, MN fervenza.fernando@mayo.edu.
Zitieren
APA
Soler, M. J., Glassock, R. J., & Fervenza, F. C. (2023). Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. New England Journal of Medicine. https://doi.org/10.1056/nejmc2304780
Vancouver
Soler MJ, Glassock RJ, Fervenza FC. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. New England Journal of Medicine. 2023. doi:10.1056/nejmc2304780
BibTeX
@article{Soler2023,
author = {Soler, Maria Jose and Glassock, Richard J and Fervenza, Fernando C},
title = {Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants},
journal = {New England Journal of Medicine},
year = {2023},
doi = {10.1056/nejmc2304780}
}
EUVIMED